JP2021528386A5 - - Google Patents

Info

Publication number
JP2021528386A5
JP2021528386A5 JP2020568772A JP2020568772A JP2021528386A5 JP 2021528386 A5 JP2021528386 A5 JP 2021528386A5 JP 2020568772 A JP2020568772 A JP 2020568772A JP 2020568772 A JP2020568772 A JP 2020568772A JP 2021528386 A5 JP2021528386 A5 JP 2021528386A5
Authority
JP
Japan
Prior art keywords
subject
alkyl
vmat2 inhibitor
composition
pharmaceutically acceptable
Prior art date
Application number
JP2020568772A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019241555A5 (https=
JP2021528386A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037046 external-priority patent/WO2019241555A1/en
Publication of JP2021528386A publication Critical patent/JP2021528386A/ja
Publication of JPWO2019241555A5 publication Critical patent/JPWO2019241555A5/ja
Publication of JP2021528386A5 publication Critical patent/JP2021528386A5/ja
Priority to JP2024104749A priority Critical patent/JP2024114905A/ja
Withdrawn legal-status Critical Current

Links

JP2020568772A 2018-06-14 2019-06-13 Vmat2インヒビター化合物、上記化合物に関する組成物および方法 Withdrawn JP2021528386A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024104749A JP2024114905A (ja) 2018-06-14 2024-06-28 Vmat2インヒビター化合物、上記化合物に関する組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684935P 2018-06-14 2018-06-14
US62/684,935 2018-06-14
PCT/US2019/037046 WO2019241555A1 (en) 2018-06-14 2019-06-13 Vmat2 inhibitor compounds, compositions, and methods relating thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024104749A Division JP2024114905A (ja) 2018-06-14 2024-06-28 Vmat2インヒビター化合物、上記化合物に関する組成物および方法

Publications (3)

Publication Number Publication Date
JP2021528386A JP2021528386A (ja) 2021-10-21
JPWO2019241555A5 JPWO2019241555A5 (https=) 2022-06-16
JP2021528386A5 true JP2021528386A5 (https=) 2022-06-16

Family

ID=67263041

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020568772A Withdrawn JP2021528386A (ja) 2018-06-14 2019-06-13 Vmat2インヒビター化合物、上記化合物に関する組成物および方法
JP2024104749A Pending JP2024114905A (ja) 2018-06-14 2024-06-28 Vmat2インヒビター化合物、上記化合物に関する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024104749A Pending JP2024114905A (ja) 2018-06-14 2024-06-28 Vmat2インヒビター化合物、上記化合物に関する組成物および方法

Country Status (16)

Country Link
EP (2) EP4691560A3 (https=)
JP (2) JP2021528386A (https=)
KR (1) KR20210021006A (https=)
CN (1) CN112638387A (https=)
AU (1) AU2019287524A1 (https=)
BR (1) BR112020024018A2 (https=)
CA (1) CA3100694A1 (https=)
EA (1) EA202092750A1 (https=)
IL (1) IL278758A (https=)
JO (1) JOP20200298A1 (https=)
MA (1) MA52896A (https=)
MX (1) MX2020013004A (https=)
PH (1) PH12020552088A1 (https=)
SG (1) SG11202011544UA (https=)
TW (1) TW202011963A (https=)
WO (1) WO2019241555A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193767A (en) 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
ES3024958T3 (en) 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 特定のvmat2インヒビターを投与するための方法
EP3784237B1 (en) 2018-04-25 2023-11-01 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US20250000805A1 (en) * 2021-10-29 2025-01-02 Neurocrine Biosciences, Inc. Valbenazine compositions

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
PL2081929T3 (pl) * 2006-11-08 2013-06-28 Neurocrine Biosciences Inc Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2771539A1 (en) 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
US8782398B2 (en) 2012-06-26 2014-07-15 Intel Corporation Secure user presence detection and authentication
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
NZ760790A (en) 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
WO2015171802A1 (en) 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
CA2974540C (en) * 2015-02-06 2023-09-26 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
EA036837B1 (ru) 2015-06-23 2020-12-25 Нейрокрин Байосайенсиз, Инк. Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств
TW202345829A (zh) * 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪(valbenazine)於治療精神分裂症或情感性精神分裂症之用途
CN110678181A (zh) 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
JP7250692B2 (ja) 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
JOP20190239A1 (ar) * 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
ES3024958T3 (en) * 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto

Similar Documents

Publication Publication Date Title
JP2021528386A5 (https=)
TWI374196B (en) Method of forming dielectric films, new precursors and their use in the semi-conductor manufacturing
JP6987859B2 (ja) Magl阻害剤
JP7745630B2 (ja) Yap/taz-tead腫瘍性タンパク質の阻害剤、その合成及び使用
US12486226B2 (en) Cannabinoid derivatives
TWI297687B (en) Linezolid-crystal form ii
JP2006500403A (ja) キノリルプロピルピペリジン誘導体およびその抗菌性物質としての使用
JP2009538910A5 (https=)
JP2009531404A5 (https=)
JPWO2019014100A5 (https=)
JP2007514691A5 (https=)
PT97510A (pt) Processo de preparacao de novos derivados da 2-metoxifenilpiperazina
JPH02290841A (ja) 新規化合物、その製法及びそれを含む医薬組成物
JPH07502022A (ja) トリアゾール抗真菌剤
JP2010520276A5 (https=)
JP2011529069A5 (https=)
Dimopoulos et al. Mechanistic studies on the O-directed free-radical hydrostannation of disubstituted acetylenes with Ph3SnH and Et3B and on the iodination of allylically oxygenated α-triphenylstannylalkenes
JPWO2019241555A5 (https=)
JP2005500370A5 (https=)
JP2025541667A (ja) ピペリジン置換安息香酸系化合物、その医薬組成物および使用
Durley et al. Chiral N, N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein
JP2007529492A (ja) β−アミノアルコール類を用いる炎症性障害及び疼痛の治療
Davies et al. Absolute Configuration Assignment by Asymmetric Syntheses of the Homalium Alkaloids (−)-(R, R, R)-Hoprominol and (−)-(4′ S, 4 ″R, 2‴ R)-Hopromalinol
JPH05194491A (ja) イミダゾリルメチル−ピリジン
US8013157B2 (en) Synthesis of unsaturated piperidines from piperidones with a silyl reagent